Trial Profile

A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talazoparib (Primary)
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Squamous cell cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms NEOTALA
Sponsors Pfizer

03 Oct 2023 Results published in the Oncologist
08 Jun 2021 Results of a biomarker analysis assessing tumor BRCA mutational status and zygosity and overall mutational landscape in patients treated with Talazoparib for whom biomarker results are available presented at the 57th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com